• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 30Risperidone vs. Aripiprazole (Acute treatment)

Outcome or SubgroupkTotal NStatistical MethodEffect [95% CI]
8.1 Global state: 1. CGI-S (Change from baseline) (short-term)183MD (IV, Fixed, 95% CI)−0.40 [−0.86, 0.06]
8.2 Global state: 1. CGI-I (Change from baseline) (short-term)183MD (IV, Fixed, 95% CI)−0.40 [−0.96, 0.16]
8.3 Mental state: 1. PANSS total (change from baseline) (short-term)183MD (IV, Fixed, 95% CI)−1.50 [−9.16, 6.16]
8.4 Leaving the study early: 1. Any reason (short-term)2384RR (M-H, Fixed, 95% CI)1.07 [0.80, 1.42]
8.5 AE: 1. Metabolic side effects - Weight gain (≥7% increase from baseline) (short-term)2383RR (M-H, Fixed, 95% CI)1.45 [0.72, 2.93]
8.6 AE: 1. Metabolic side effects - Weight gain (short-term)183MD (IV, Fixed, 95% CI)0.60 [−0.44, 1.64]
8.7 AE: 1. Metabolic side effects - Prolactin change (increased level above 23–25 ng/mL) (short-term)2367RR (M-H, Fixed, 95% CI)23.77 [12.51, 45.13]
8.8 AE: 1. Metabolic side effects - Fasting glucose (change from baseline, mg/dL) (short- term)183MD (IV, Fixed, 95% CI)−6.80 [−19.70, 6.10]
8.9 AE: 1. Metabolic side effects - Total cholesterol (change from baseline, mg/dL) (short- term)183MD (IV, Fixed, 95% CI)22.30 [4.91, 39.69]
8.10 AE: 1. Metabolic side effects - Serum prolactin (Change from baseline, mg/dL) (short-term)183MD (IV, Fixed, 95% CI)64.40 [33.89, 94.91]
8.11 AE: 2. Neurologic side effects - Needing additional anticholinergic medication (short-term)183RR (M-H, Fixed, 95% CI)1.68 [0.89, 3.17]
8.12 AE: 2. Neurologic side effects (treatment-emergent) (short-term)
 8.12.1 Any extrapyramidal event1300RR (M-H, Fixed, 95% CI)1.00 [0.70, 1.43]
 8.12.2 Tremor1300RR (M-H, Fixed, 95% CI)0.21 [0.05, 0.90]
 8.12.3 Hypertonia1300RR (M-H, Fixed, 95% CI)6.09 [1.69, 22.00]
 8.12.4 Agitation2383RR (M-H, Fixed, 95% CI)0.74 [0.48, 1.13]
 8.12.5 Akathisia2383RR (M-H, Fixed, 95% CI)0.86 [0.51, 1.45]
 8.12.6 Dystonia1300RR (M-H, Fixed, 95% CI)10.15 [1.20, 85.72]
 8.12.7 Extrapyramidal disorder183RR (M-H, Fixed, 95% CI)1.92 [0.73, 5.04]
 8.12.8 Extrapyramidal syndrome1300RR (M-H, Fixed, 95% CI)0.13 [0.01, 2.33]
8.13 AE: 2. Neurologic side effects - Simpson-Angus Scale (SAS; change from baseline) (short-term)183MD (IV, Fixed, 95% CI)1.50 [0.47, 2.53]
8.14 AE: 2. Neurologic side effects - Barnes Akathisia Scale (BAS; change from baseline) (short-term)183MD (IV, Fixed, 95% CI)0.40 [−0.15, 0.95]
8.15 AE: 2. Neurologic side effects - Involuntary Movement Scale (AIMS; change from baseline) (short-term)183MD (IV, Fixed, 95% CI)0.80 [−0.10, 1.70]
8.16 AE: 3. Autonomic side effects (short-term)
 8.16.1 Increased salivation1300RR (M-H, Fixed, 95% CI)0.76 [0.21, 2.81]
 8.16.2 Dry mouth1300RR (M-H, Fixed, 95% CI)1.18 [0.48, 2.91]
 8.16.3 Rhinitis1300RR (M-H, Fixed, 95% CI)3.05 [1.29, 7.21]
 8.16.4 Blurred vision1300RR (M-H, Fixed, 95% CI)1.02 [0.31, 3.29]
8.17 AE: 4. Cardiovascular side effects (short-term)
 8.17.1 Dizziness/lightheadedness2383RR (M-H, Fixed, 95% CI)1.26 [0.67, 2.35]
 8.17.2 Tachycardia1300RR (M-H, Fixed, 95% CI)4.35 [1.83, 10.33]
8.18 AE: 4. Cardiovascular side effects - QTc prolongation (Change in QTc interval ms) (short-term)183MD (IV, Random, 95% CI)9.00 [-6.81, 24.81]
8.19 AE: 5. Gastrointestinal side effects (short-term)
 8.19.1 Constipation2383RR (M-H, Fixed, 95% CI)1.22 [0.66, 2.26]
 8.19.2 Vomiting2383RR (M-H, Fixed, 95% CI)0.62 [0.30, 1.26]
 8.19.3 Dyspepsia1300RR (M-H, Fixed, 95% CI)0.76 [0.41, 1.41]
 8.19.4 Nausea2383RR (M-H, Fixed, 95% CI)1.43 [0.74, 2.77]
8.20 AE: 6. Sedation (short-term)
 8.20.1 Day time sleepiness - increase (somnolence)1300RR (M-H, Fixed, 95% CI)1.24 [0.67, 2.30]
 8.20.2 Asthenia1300RR (M-H, Fixed, 95% CI)0.76 [0.31, 1.89]
8.21 AE: 7. Sexual dysfunction (short-term)
 8.21.1 Vaginitis1300RR (M-H, Fixed, 95% CI)1.02 [0.09, 11.06]
8.22 AE: 8. Menstrual problems (short-term)
 8.22.1 Dysmenorrhea1300RR (M-H, Fixed, 95% CI)0.29 [0.02, 5.53]
8.23 AE: 9. Dermatological system (short-term)1300RR (M-H, Fixed, 95% CI)1.16 [0.50, 2.67]
 8.23.1 Skin rash1300RR (M-H, Fixed, 95% CI)1.16 [0.50, 2.67]
8.24 AE: 10. Other side effects (short-term)
 8.24.1 Pharyngitis2383RR (M-H, Fixed, 95% CI)0.44 [0.11, 1.67]
 8.24.2 Diarrhoea2383RR (M-H, Fixed, 95% CI)1.17 [0.52, 2.65]
 8.24.3 Anxiety2383RR (M-H, Fixed, 95% CI)0.95 [0.59, 1.54]
 8.24.4 Insomnia2383RR (M-H, Fixed, 95% CI)0.77 [0.52, 1.14]
 8.24.5 Psychotic disorder183RR (M-H, Fixed, 95% CI)0.78 [0.35, 1.74]
 8.24.6 Infection1300RR (M-H, Fixed, 95% CI)0.51 [0.11, 2.35]
 8.24.7 Myalgia1300RR (M-H, Fixed, 95% CI)0.34 [0.08, 1.48]
 8.24.8 Upper respiratory infection1300RR (M-H, Fixed, 95% CI)1.48 [0.61, 3.55]
8.25 AE: 10. Other side effects - pain & injury (short-term)
 8.25.1 Abdominal pain183RR (M-H, Fixed, 95% CI)0.20 [0.01, 3.83]
 8.25.2 Headache2383RR (M-H, Fixed, 95% CI)0.95 [0.67, 1.35]
 8.25.3 Upper abdominal pain183RR (M-H, Fixed, 95% CI)0.36 [0.04, 3.08]
 8.25.4 Toothache/dental disorder2383RR (M-H, Fixed, 95% CI)1.83 [0.78, 4.26]
 8.25.5 Back pain1300RR (M-H, Fixed, 95% CI)2.84 [0.93, 8.73]
 8.25.6 Accidental injury1300RR (M-H, Fixed, 95% CI)0.18 [0.01, 3.29]
 8.25.7 Pain1300RR (M-H, Fixed, 95% CI)0.62 [0.27, 1.39]
 8.25.8 Joint disorder1300RR (M-H, Fixed, 95% CI)5.08 [1.00, 25.70]

From: 10, Clinical evidence summary tables

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.